ArticleCells2022

Assessment of FDA-Approved Drugs as a Therapeutic Approach for Niemann-Pick Disease Type C1 Using Patient-Specific iPSC-Based Model Systems.

Christin Völkner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.